Donna Rivera, PharmD., MSc., is Associate Director of Pharmacoepidemiology at the FDA, with interests in translating real world data into real world evidence. She previously was a Scientific Project Officer in Surveillance Informatics Branch of the Surveillance Research Program in the Division of Cancer Control and Population Sciences at the National Cancer Institute (NCI). Her research focuses on the use of pharmacoepidemiology and pharmacosurveillance to evaluate medication utilization and health outcomes across the changing cancer treatment landscape, with an emphasis on targeted oral agents, immunotherapies, and vaccines. She works on projects which enhance the availability and quality of treatment data within SEER through various external collaborations, including evaluation of novel methodologies and linkages for precision cancer surveillance.
Dr. Rivera earned her Doctor of Pharmacy and Master of Science in Pharmaceutical Sciences with a concentration in Pharmaceutical Outcomes and Policy from the University of Florida College of Pharmacy. She did her fellowship training at NCI in the Clinical and Translational Epidemiology Branch of the Epidemiology and Genomics Research Program. Prior to NCI, Donna worked on Phase I clinical trials at Stiefel, a GlaxoSmithKline company.
She is the HemOnc.org Associate Editor of Clinical Pharmacology.